Research
The CFB wants to go even further in supporting patients and enabling them to live better during and after their radiotherapy treatment.
With a view to improving the effectiveness of radiotherapy while limiting side effects (or toxicities), it develops and participates in numerous national and international research projects.
BASIC RESEARCH
Research is a field close to the heart of our Director, Professor Guillaume Vogin, who has himself been appointed "affiliated clinician-scientist" at the Luxembourg Institute of Health (LIH) with the aim of developing a research program focused on the mechanisms of toxicity induced by radiotherapy.
Professor Vogin's research will include molecular studies of radio-toxicity as well as clinical studies aimed at improving the effectiveness of radiotherapy while limiting side effects. The research program plans to integrate quantitative imaging data with a radiomic approach in the diagnosis and monitoring of sequelae. The studies will search for other individual biomarkers of radiosensitivity using new research avenues developed at LIH.
CLINICAL RESEARCH
Discover all our current projects and clinical trials.
APRILUX
Neolys Diagnostics, in collaboration with Prof. Vogin, has developed a radiation sensitivity test called "RADIODTECT" which, using a blood sample, can detect a potential risk of toxicity in patients. Thanks to the support of Fondation Cancer, the CFB is able to offer this test to patients as part of the APRILUX clinical study. Involving 200 consecutive patients who have been referred for curative radiotherapy at the CFB, it will enable the severity of the side effects described by patients to be observed and the predictive capabilities of the blood test to be evaluated.
PART
PART is a phase 2 study (efficacy and safety trial) launched in 2022 and focusing on selective irradiation of retroperitoneal lymph nodes in patients with pN1 prostate cancer. Its aim is to assess whether irradiation of a larger volume of pelvic lymph nodes AND para-aortic lymph nodes offers better chances of cure and fewer recurrences than irradiation of pelvic lymph nodes alone.
INOTREM
This pilot study, conducted since 2022 by the CFB and INOTREM (a company specializing in immunotherapy for acute inflammatory syndromes), is looking at the predictive value of TREM1 expression and activation in radio-induced breast inflammation and fibrosis. This study, conducted in collaboration with the IBBL (for sample management), has been rolled out at several sites in France (ICL and CHR in Metz) and at the CFB.
At the CFB, radio-induced toxicities are monitored in the short and long term through projects such as "CK Boost pelvien (prostate)" and "IMRT Sein." The data collected, which is currently being analyzed, will help us understand the onset of these toxicities and prevent them.
SCIENTIFIC PUBLICATIONS
Find a publication
Outcome analysis of HDR compared to PDR IGABT in locally advanced cervical cancer: a single-center cohort analysis
Johanne Hermesse, Clémence Pleyers, Christine Gennigens, Marjolein De Cuypere, Pierre Lovinfosse, Laurence Seidel Statistician, Philippe Coucke, Frédéric Kridelka
Strahlenther Onkol. 2023 Feb;199(2):141-148. doi: 10.1007/s00066-022-01982-7. Epub 2022 Aug 9.
Stereotactic focal radiotherapy as an alternative treatment for low-risk prostate cancer: results of a single-arm monocenter Phase-II trial
Paul V. Nguyen 1,2*, Bertrand Donneaux 2, Céline Louis 2, Szusa Bodgal 2, Sven Philippi 2, Sylvie Biver 2, Bérangère Frédérique 2, Ludovic Harzé 2, Yves Lasar 3, Guillaume Vogin 2, Philippe Nickers2,4
Frontiers in oncology
Could conventionally fractionated radiation therapy coupled with stereotactic body radiation therapy improve local control in bone oligometastases?
Py JF, Salleron J, Vogin G, Courrech F, Teixeira P, Colnat-Coulbois S, Baumard F, Thureau S, Supiot S, Peiffert D, Oldrini G, Faivre JC.
Cancer Radiother. 2023 Feb;27(1):1-10. doi: 10.1016/j.canrad.2022.03.002. Epub 2023 Jan 12.
PMID: 36641333
The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review.
Pereira S, Orlandi E, Deneuve S, Barcellini A, Chalaszczyk A, Behm-Ansmant I, Hettal L, Rancati T, Vogin G, Thariat J.
Cancers (Basel). 2022 Dec 19;14(24):6252. doi: 10.3390/cancers14246252.
PMID: 36551737 Free PMC article. Review.
Target volume delineation for radiotherapy of meningiomas: an ANOCEF consensus guideline.
Martz N, Salleron J, Dhermain F, Vogin G, Daisne JF, Mouttet-Audouard R, Tanguy R, Noel G, Peyre M, Lecouillard I, Jacob J, Attal J, Charissoux M, Veresezan O, Hanzen C, Huchet A, Latorzeff I, Coutte A, Doyen J, Stefan D, Feuvret L, Garcia GCTE, Royer P.
Radiat Oncol. 2023 Jul 5;18(1):113. doi: 10.1186/s13014-023-02300-w.
PMID: 37408055 Free PMC article. Review.
Lighting Up the Fire in the Microenvironment of Cold Tumors: A Major Challenge to Improve Cancer Immunotherapy.
Benoit A, Vogin G, Duhem C, Berchem G, Janji B.
Cells. 2023 Jul 5;12(13):1787. doi: 10.3390/cells12131787.
PMID: 37443821 Free PMC article. Review.
Multicentric development and evaluation of 18F-FDG PET/CT and MRI radiomics models to predict para-aortic lymph node involvement in locally advanced cervical cancer.
Lucia F, Bourbonne V, Pleyers C, Dupré PF, Miranda O, Visvikis D, Pradier O, Abgral R, Mervoyer A, Classe JM, Rousseau C, Vos W, Hermesse J, Gennigens C, De Cuypere M, Kridelka F, Schick U, Hatt M, Hustinx R, Lovinfosse P.
Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2514-2528. doi: 10.1007/s00259-023-06180-w. Epub 2023 Mar 9.PMID: 36892667